ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial... Read more.
Wandke Consulting Rebrands as Wandke Accessibility
Innovative disability-owned agency specializing in helping companies create accessible services, platforms, and environments unveils new website logo and client... Read more.
Global ADC (Antibody Drug Conjugates) Market Research Report 2023-2035: Focus on ADC Linker and ADC Conjugation Technologies – Over 420 ADCs are Currently Being Evaluated – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) – Distribution by Generation... Read more.
Ryan Recognized as a Best Workplace in North Texas by the Dallas Business Journal for 13th Consecutive Year
DALLAS–(BUSINESS WIRE)–Ryan, a leading global tax services and software provider, has recently been named to the 2023 Dallas Business Journal’s Best... Read more.
At AES 2023, Taqtile Previews Spatial Computing Work-Instruction Platform on HTC VIVE XR Elite
Taqtile to Leverage Color Passthrough Capabilities of Headset in Manifest Demonstration at HTC VIVE Booth HOUSTON–(BUSINESS WIRE)–Taqtile, Inc., will... Read more.
Connected Medication Compliance Monitoring Devices Surge to 4.4 Million Units in 2022, Set to Reach 8.2 Million Units by 2027: New Report Reveals Remarkable Market Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “The Medication Compliance Monitoring Market – 1st Edition” report has been added to ResearchAndMarkets.com’s... Read more.
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with... Read more.
FiscalNote Expands EU Tracking Capabilities With AI-Powered EU Parliament Transcripts and Stakeholder Coverage of All Parliament Members
Expanded EUIT Capabilities Enable Customers to Track All 705 Members of European Parliament, and Receive Near-Immediate AI-Generated Transcripts of EU Parliament... Read more.
Acuity Earns Top Claims Award at Excellence in Insurance, Sponsored by Insurity
HARTFORD, Conn.–(BUSINESS WIRE)–Acuity recently received the Claims Champion of the Year award, the only insurer nationwide to be recognized. The award... Read more.
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was... Read more.